Skip to content

Discovery of Pyrazolopyrimidines as Potent and Orally Bioavailable MRGPRX2 Antagonists

Oct 2026 · ACS Medicinal Chemistry Letters · 0 citations · 13 references

TL;DR

The discovery of a pyrazolopyrimidine series as potent and orally bioavailable MRGPRX2 antagonists and establish the pyrazolopyrimidine chemotype as a promising scaffold for inhibition of MRGPRX2 signaling are established.

Abstract

The Mas-related G protein-coupled receptor X2 (MRGPRX2) mediates IgE-independent mast cell activation and is implicated in pseudoallergic drug reactions, chronic urticaria, atopic dermatitis, rosacea, neurogenic inflammation, and other mast cell-mediated disorders. Herein, we report the discovery of a pyrazolopyrimidine series as potent and orally bioavailable MRGPRX2 antagonists. A scaffold hybridization strategy, supported by systematic structure–activity relationship studies, yielded antagonists with nanomolar activity in both Gq/IP1 and beta-arrestin cellular assays. Addressing solubility limitations and CYP inhibition liability, while maintaining favorable pharmacokinetic properties, led to the identification of INCB187175 (compound 23), which exhibits good cellular potency and robust oral exposure across preclinical species. Importantly, functional activity was validated in a beta-hexosaminidase release assay using primary human mast cells, demonstrating potent inhibition of MRGPRX2-mediated degranulation. This activity translated in vivo, where INCB187175 effectively suppressed mast cell activation in an Evans blue extravasation assay. These findings establish the pyrazolopyrimidine chemotype as a promising scaffold for inhibition of MRGPRX2 signaling and support INCB187175 as a compelling drug candidate for further development in mast cell-mediated diseases.

View source

Similar papers

Review Oct 2026

MRGPRX2 in Allergic and Immune-Mediated Diseases: Mechanisms, Clinical Relevance, and Therapeutic Translation

Current data support MRGPRX2 as an investigational endotype-defining pathway rather than a universal driver of allergic or immune-mediated disease, and integrates these findings with receptor pharmacology and early clinical development.

W. Reinisch, Yi Li, Peng-Ju Xiong et al. · 0 citations
Open access Oct 2026

Discovery of YA8026, an optimized human constitutive androstane receptor activator from a novel ML241-derived scaffold.

A new non-CITCO chemotype for hCAR activation is established and YA8026 is identified as a promising lead compound for further development following the discovery of a structurally distinct class of hCAR activators based on the 2,4-diaminopyrimidine scaffold of ML241.

Yong Ai, Lin-Hao Li, Caitlin Lynch et al. · 0 citations
Sep 2026

Design, Synthesis, and Biological Evaluation of Novel Arylethanone Oxime Ether Derivatives as Potent S1PR1 Agonists for Ulcerative Colitis Therapy.

S1PR1 is a clinically validated key therapeutic target for ulcerative colitis (UC), but approved S1PR1 agonists universally suffer from the core drawback of S1PR3-mediated cardiotoxicity. Herein, we designed and synthesized multiple novel arylethanone oxime ethers-based S1PR1 agonists. Among them, compound 13d exhibite...

Lan-Yan Ma, Yang Yang, Xiao Wang et al. · 0 citations
Oct 2026

Pyridazino-Indoles as Phenol Bioisosteres for Potent Inhibition of NLRP3

Aberrant activation of the NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome drives chronic diseases, necessitating robust therapeutic inhibitors. Despite the promise of phenol-based pyridazines, we sought to evaluate the possibility of replacing the phenol moiety. This article presents the medicin...

L. Bouché, S. Mesch, S. Steiner et al. · 0 citations
Sep 2026

Discovery of potent, selective, and orally bioavailable monocyclic pyridine-based PKMYT1 inhibitors that synergize with CHK1 inhibition in replication-stressed cancer cells.

PKMYT1 mediates the inhibitory phosphorylation of CDK1 and represents a promising synthetic lethal target in p53-deficient or CCNE1-amplified malignancies. A series of PKMYT1 inhibitors featuring a novel monocyclic pyridine core structure was discovered, exhibiting improved selectivity and enhanced drug-like properties...

Ying Sun, Hong-Zhu Chu, Yong-Gang Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.